Drug Profile
XR 5944
Alternative Names: MLN 944; XR5944Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Xenova Group
- Class Antineoplastics; Phenazines
- Mechanism of Action DNA intercalators; DNA topoisomerase I inhibitors; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV)
- 16 Mar 2005 Data from a media release have been added to the adverse events and Cancer therapeutic trials sections
- 29 Nov 2004 Data presented at the British Cancer Research Meeting 2004 (BCRM-2004) have been added to the pharmacokinetics section